6533b828fe1ef96bd1287b13
RESEARCH PRODUCT
Drug-induced chromatin accessibility changes associate with sensitivity to liver tumor promotion
Marc AltorferColin J. HendersonColin J. HendersonMagdalena WestphalJohanna BeilUlrike NaumannJuliane PernerMichael SchwarzMichael SchwarzValerie DubostAntonio VitobelloAntonio VitobelloLaurent MorawiecJiang ZhuJonathan G. MoggsJonathan G. MoggsC. Roland WolfC. Roland WolfMark BorowskyRémi TerranovaArne MuellerKaren KapurAlberto Del Rio-espinolasubject
Male0301 basic medicine63Health Toxicology and MutagenesisGene regulatory networkPlant ScienceSMADBiologyBiochemistry Genetics and Molecular Biology (miscellaneous)Epigenesis GeneticMice03 medical and health sciences0302 clinical medicinemedicineAnimalsHumansGene Regulatory NetworksEpigeneticsWnt Signaling PathwayTranscription factorResearch ArticlesEcologyGene Expression ProfilingLiver NeoplasmsWnt signaling pathwayComputational Biology11Chromatin Assembly and Disassemblymedicine.diseaseChromatin3. Good healthChromatin030104 developmental biologyPhenobarbital030220 oncology & carcinogenesisCancer researchTumor promotionLiver cancerResearch Articledescription
This work explores quantitative chromatin accessibility, transcriptional and cis-acting gene regulatory variations underlying mouse strain–specific differences in drug-induced liver tumor promotion sensitivity.
year | journal | country | edition | language |
---|---|---|---|---|
2019-10-01 | Life Science Alliance |